Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970321 | 0.94 | CNR1 (0.58) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14873812 | 0.88 | KMT2A (0.61) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL16129581 | 0.87 | SIRT1 (0.59) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL15532876 | 0.86 | CNR1 (0.63) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL15829520 | 0.86 | CNR1 (0.59) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL23456343 | 0.84 | MEN1 (0.74) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL14097983 | 0.84 | CNR1 (0.56) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL30831949 | 0.83 | CNR1 (0.67) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL598010 | 0.83 | CNR1 (0.66) | CNR1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL9970719 | 0.82 | CNR1 (0.55) | CNR1RAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9446064-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2016-09-01 | — | — | US | disclosed |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. | 2016-09-01 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2016-02-18 | — | — | US | disclosed |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2646454-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2646455-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| CN-103339139-A | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof | EPIZYME INC | 2013-10-02 | — | — | CN | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012075500-A2 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | CNR1 4579/4885RAB9A 2637/4885MEN1 2681/4885 |
| US-20140073597-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | CNR1 4471/4885RAB9A 2826/4885MEN1 3853/4885 |
| US-20130310334-A1 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof | TPMT, HNMT, EHMT1 | CNR1 4471/4885RAB9A 2826/4885MEN1 3853/4885 |
| US-20160251390-A1 | 7-DEAZAPURINE MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | TPMT, HNMT, EHMT1 | CNR1 4471/4885RAB9A 2826/4885MEN1 3853/4885 |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | CNR1 4059/4885RAB9A 3514/4885MEN1 3412/4885 |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | CNR1 4503/4885RAB9A 2581/4885MEN1 3138/4885 |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | CNR1 4059/4885RAB9A 3514/4885MEN1 3412/4885 |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | CNR1 4383/4885RAB9A 2086/4885MEN1 3936/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | CNR1 4579/4885RAB9A 2637/4885MEN1 2681/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | CNR1 4503/4885RAB9A 2581/4885MEN1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.